- Conditions
- Long QT Syndrome
- Interventions
- Placebo, Ranolazine
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Andersen-Tawil Syndrome, Andersen Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- San Francisco, California • Kansas City, Kansas • Rochester, New York + 1 more
- Conditions
- Congenital Disorders
- Interventions
- Epinephrine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiac Toxicity
- Interventions
- Moxifloxacin
- Drug
- Lead sponsor
- Haiyan Li
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Andersen-Tawil Syndrome
- Interventions
- Potassium, Acetazolamide
- Dietary Supplement · Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Cardiac Pacing, Artificial, Cardiac Pacemaker, Artificial
- Interventions
- Medtronic Dual-Chamber Pacemaker, Medtronic SelectSecure 3830 Lead
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 16
- States / cities
- Bridgeport, Connecticut • Clearwater, Florida • Hudson, Florida + 13 more
- Conditions
- Arrhythmia
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2031
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cardiac Death, Cardiac Death, Sudden, Wolf Parkinson White Syndrome
- Interventions
- Ablation, Standard of care without ablation
- Procedure
- Lead sponsor
- United States Naval Medical Center, San Diego
- Federal
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- CPVT1, Heart Defects, Congenital, Heart Diseases, Ventricular Tachycardia
- Interventions
- CRD-4730, Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Cleveland, Ohio • Houston, Texas
- Conditions
- Long QT Syndrome
- Interventions
- LQT-1213, Placebo, Dofetilide 250 μg Cap
- Drug
- Lead sponsor
- Thryv Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Long QT Syndrome, Familial Hypercholesterolemia, Ethics, Genetic Testing
- Interventions
- Direct contact of family members for cascade screening of relevant variants
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Arrhythmia
- Interventions
- quinidine, no therapy
- Drug
- Lead sponsor
- International Registry of Asymptomatic Brugada Syndrome
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Cardiovascular Diseases
- Interventions
- Energy drink, Placebo drink
- Other
- Lead sponsor
- University of the Pacific
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Stockton, California
- Conditions
- Long QT Syndrome (LQTS) 2
- Interventions
- baseline lead-in, THRV-1268
- Other · Drug
- Lead sponsor
- Thryv Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more
- Conditions
- Prolonged QT Interval
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hypertrophic Cardiomyopathy, Long QT Syndrome
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 8 Years to 60 Years
- Enrollment
- 4,299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Orange, California • San Diego, California + 24 more
- Conditions
- Transcatheter Aortic Valve Replacement
- Interventions
- ECG monitoring for Conduction Disturbances
- Other
- Lead sponsor
- Cara Medical Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Long QT Syndrome, Abnormalities, Drug-Induced
- Interventions
- Progesterone, Ibutilide, Testosterone, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Ventricular Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Tachycardia, Sudden Cardiac Death
- Interventions
- ECG, Echocardiography, Cardiac MRI, Ambulatory ECG recording, Cardiac EP study, All study subjects will undergo sample collection for genetic testing.
- Diagnostic Test · Genetic
- Lead sponsor
- Sheri Kashmir Institute of Medical Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Congenital Disorders
- Interventions
- Not listed
- Lead sponsor
- Children's Healthcare of Atlanta
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Long QT Syndrome
- Interventions
- QTc Meter
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 5 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy
- Interventions
- Tramadol HCl, 50 mg, Placebo
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Long QT Syndrome
- Interventions
- LQT-1213, Placebo
- Drug · Other
- Lead sponsor
- Thryv Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California